| For: | Limanskiy V, Vyas A, Chaturvedi LS, Vyas D. Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease. World J Gastroenterol 2019; 25(18): 2177-2187 [PMID: 31143069 DOI: 10.3748/wjg.v25.i18.2177] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i18/2177.htm |
| Number | Citing Articles |
| 1 |
Shahad K. Alsaiari, Behnaz Eshaghi, Bujie Du, Maria Kanelli, Gary Li, Xunhui Wu, Linzixuan Zhang, Mehr Chaddah, Alicia Lau, Xin Yang, Robert Langer, Ana Jaklenec. CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells. Nature Reviews Materials 2024; 10(1) doi: 10.1038/s41578-024-00725-7
|
| 2 |
Xiaoting Xu, Yuping Zhang, Guoxin Huang, Ansu Perekatt, Yan Wang, Lei Chen. Advances and applications of gut organoids: modeling intestinal diseases and therapeutic development. Life Medicine 2025; 4(2) doi: 10.1093/lifemedi/lnaf012
|
| 3 |
Xuanqi Ren, Ziyang Zhou, Lingkai Kong, Yibo Guo, Yan Liu, Jiazhen Li, Xiaosong Gu, Chunping Jiang, Junhua Wu. Re-balancing immunity with CRISPR-Cas9: Novel strategies for cancer and autoimmune disorders. Biotechnology Advances 2026; 90 doi: 10.1016/j.biotechadv.2026.108921
|
| 4 |
Aravind Sundararaman, Prakash M. Halami. Genome editing of probiotic bacteria: present status and future prospects. Biologia 2022; 77(7) doi: 10.1007/s11756-022-01049-z
|
| 5 |
Martina Poletti, Kaline Arnauts, Marc Ferrante, Tamas Korcsmaros. Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD. Journal of Crohn's and Colitis 2021; 15(7) doi: 10.1093/ecco-jcc/jjaa257
|
| 6 |
Sidra Anwar, Alvina Gul, Rumeza Hanif. Targeted Genome Engineering via CRISPR/ Cas9 in Plants. 2024; doi: 10.1016/B978-0-443-26614-0.00014-X
|
| 7 |
|
| 8 |
Yingying Chen, Dongyue Li, Liying Sun, Kai Qi, Lijun Shi. Pharmacological inhibition of toll-like receptor 4 with TLR4-IN-C34 modulates the intestinal flora homeostasis and the MyD88/NF-κB axis in ulcerative colitis. European Journal of Pharmacology 2022; 934 doi: 10.1016/j.ejphar.2022.175294
|
| 9 |
Li-Feng Sun, Zhi Liu, Lu Guo, Wen-Xin Shi, Hai-Yan Liu, Yu-Juan Qi, Bao-Qi Chen, Zhi-Yi Wang, Yuan Chen. Clinical characteristics and genetic causes of unexplained pediatric liver disease. World Journal of Hepatology 2025; 17(10): 109770 doi: 10.4254/wjh.v17.i10.109770
Abstract(87) |
Core Tip(65) |
Full Article(HTML)(265)
|
Full Article (PDF)-1953K(80)
|
Full Article with Cover (PDF)-2265K(74)
|
Full Article (XML)-105K(34)
|
Audio-826K(11)
|
Peer-Review Report-257K(33)
|
Answering Reviewers-225K(62)
|
Supplementary Material-81K(61)
|
Times Cited (1)
|
Total Visits (559)
|
Open
|
| 10 |
Rui Wang, Sean Graham, Ning Sun, Donna McCarthy, Ruoqi Peng, Jamie Erickson, Liz Oconnor, Xiaochun Zhu, Marc Wurbel, Robert Dunstan, Susan Westmoreland, Namjin Chung, Tariq Ghayur, Jijie Gu, Edda Fiebiger. CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40. PLOS ONE 2020; 15(3) doi: 10.1371/journal.pone.0228221
|
| 11 |
Miao Wu, Niandan Hu, Xianjin Du, Jie Wei. Application of CRISPR/Cas9 technology in sepsis research. Briefings in Functional Genomics 2020; 19(3) doi: 10.1093/bfgp/elz040
|
| 12 |
Zahra Khademi, Negar Mottaghi-Dastjerdi, Hamed Morad, Amirhossein Sahebkar. The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases. Autoimmunity Reviews 2025; 24(7) doi: 10.1016/j.autrev.2025.103816
|
| 13 |
Boopathi Balasubramaniam, Ransome van der Hoeven. Advancements in Modeling-Based Therapeutics and Technology for Chronic Diseases. 2026; doi: 10.1016/B978-0-443-33877-9.00010-0
|
| 14 |
Xinlong Wang, Weihua Xu, Yushan Wu, Peifeng Liu, Bing Wang, Jianfeng Li, Huili Dai. Clinical combination therapy for IBD and promising co-delivery strategies. Inflammopharmacology 2026; doi: 10.1007/s10787-026-02222-5
|
| 15 |
Ruoyi Gan, Enqi Ni, Guanyue Li, Wei Chen. A New Paradigm for Precision Drug Delivery in Inflammatory Bowel Disease: Effective Transfer, Enhanced Retention, and Pathology‐Targeting Treatment via Biomaterials and Engineered Platforms. MedComm – Biomaterials and Applications 2025; 4(3) doi: 10.1002/mba2.70022
|